|
1
|
Shamir ER and Ewald AJ: Three-dimensional
organotypic culture: Experimental models of mammalian biology and
disease. Nat Rev Mol Cell Biol. 15:647–664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kang HG, Jenabi JM, Zhang J, Keshelava N,
Shimada H, May WA, Ng T, Reynolds CP, Triche TJ and Sorensen PH:
E-cadherin cell-cell adhesion in ewing tumor cells mediates
suppression of anoikis through activation of the ErbB4 tyrosine
kinase. Cancer Res. 67:3094–3105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Desoize B and Jardillier J: Multicellular
resistance: A paradigm for clinical resistance? Crit Rev Oncol
Hematol. 36:193–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He JM, Wang FC, Qi HB, Li Y and Liang HJ:
Down-regulation of alphav integrin by retroviral delivery of small
interfering RNA reduces multicellular resistance of HT29. Cancer
Lett. 284:182–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi H, Man S, Graham CH, Kapitain
SJ, Teicher BA and Kerbel RS: Acquired multicellular-mediated
resistance to alkylating agents in cancer. Proc Natl Acad Sci USA.
90:3294–3298. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Green SK, Karlsson MC, Ravetch JV and
Kerbel RS: Disruption of cell-cell adhesion enhances
antibody-dependent cellular cytotoxicity: Implications for
antibody-based therapeutics of cancer. Cancer Res. 62:6891–6900.
2002.PubMed/NCBI
|
|
7
|
Yang Z and Zhao X: A 3D model of ovarian
cancer cell lines on peptide nanofiber scaffold to explore the
cell-scaffold interaction and chemotherapeutic resistance of
anticancer drugs. Int J Nanomedicine. 6:303–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JM, Mhawech-Fauceglia P, Lee N,
Parsanian LC, Lin YG, Gayther SA and Lawrenson K: A
three-dimensional microenvironment alters protein expression and
chemosensitivity of epithelial ovarian cancer cells in vitro. Lab
Invest. 93:528–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engl W, Arasi B, Yap LL, Thiery JP and
Viasnoff V: Actin dynamics modulate mechanosensitive immobilization
of E-cadherin at adherens junctions. Nat Cell Biol. 16:587–594.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gall TM and Frampton AE: Gene of the
month: E-cadherin (CDH1). J Clin Pathol. 66:928–932. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mattias L, Haque A, Adnan N and Akaike T:
The effects of artificial E-cadherin matrix-induced embryonic stem
cell scattering on paxillin and RhoA activation via α-catenin.
Biomaterials. 35:1797–1806. 2014. View Article : Google Scholar
|
|
12
|
Truffi M, Dubreuil V, Liang X, Vacaresse
N, Nigon F, Han SP, Yap AS, Gomez GA and Sap J: RPTPα controls
epithelial adherens junctions, linking E-cadherin engagement to
c-Src-mediated phosphorylation of cortactin. J Cell Sci.
127:2420–2432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura T, Kato Y, Fuji H, Horiuchi T,
Chiba Y and Tanaka K: E-cadherin-dependent intercellular adhesion
enhances chemoresistance. Int J Mol Med. 12:693–700.
2003.PubMed/NCBI
|
|
14
|
Govatati S, Singamsetty GK, Nallabelli N,
et al: Contribution of cyclin D1 (CCND1) and E-cadherin (CDH1)
alterations to colorectal cancer susceptibility: A case-control
study. Tumour Biol. 35:12059–12067. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yun JA, Kim SH, Hong HK, Yun SH, Kim HC,
Chun HK, Cho YB and Lee WY: Loss of E-Cadherin expression is
associated with a poor prognosis in stage III colorectal cancer.
Oncology. 86:318–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, He J, Zhong D, Li J and Liang H:
High-mobility group box 1 protein activating nuclear factor-κB to
upregulate vascular endothelial growth factor C is involved in
lymphangiogenesis and lymphatic node metastasis in colon cancer. J
Int Med Res. 43:494–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Phung YT, Barbone D, Broaddus VC and Ho M:
Rapid generation of in vitro multicellular spheroids for the study
of monoclonal antibody therapy. J Cancer. 2:507–514. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He J, Shin H, Wei X, Kadegowda AK, Chen R
and Xie SK: NPC1L1 knockout protects against colitis-associated
tumorigenesis in mice. BMC Cancer. 15:1892015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
|
21
|
Tanaka E, Hashimoto Y, Ito T, Kondo K,
Higashiyama M, Tsunoda S, Ortiz C, Sakai Y, Inazawa J and Shimada
Y: The suppression of aurora-A/STK15/BTAK expression enhances
chemosensitivity to docetaxel in human esophageal squamous cell
carcinoma. Clin Cancer Res. 13:1331–1340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DJ, Kang DH, Choi M, et al:
Peroxiredoxin-2 represses melanoma metastasis by increasing
E-cadherin/β-catenin complexes in adherens junctions. Cancer Res.
73:4744–4757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Ye X, Zhang JB, et al: PROX1
promotes hepatocellular carcinoma proliferation and sorafenib
resistance by enhancing β-catenin expression and nuclear
translocation. Oncogene. Feb 16–2015.(Epub ahead of print).
View Article : Google Scholar
|
|
24
|
Koti M, Gooding RJ, Nuin P, Haslehurst A,
Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et
al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling
networks associated with chemotherapy resistance and treatment
response in high-grade serous epithelial ovarian cancer. BMC
Cancer. 13:5492013. View Article : Google Scholar
|
|
25
|
Liu S, Wang J, Niu W, Liu E, Wang J, Peng
C, Lin P, Wang B, Khan AQ, Gao H, et al: The β6-integrin-ERK/MAP
kinase pathway contributes to chemo resistance in colon cancer.
Cancer Lett. 328:325–334. 2013. View Article : Google Scholar
|
|
26
|
Basile KJ, Abel EV, Dadpey N, Hartsough
EJ, Fortina P and Aplin AE: In vivo MAPK reporting reveals the
heterogeneity in tumoral selection of resistance to RAF inhibitors.
Cancer Res. 73:7101–7110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sui X, Kong N, Ye L, Han W, Zhou J, Zhang
Q, He C and Pan H: p38 and JNK MAPK pathways control the balance of
apoptosis and autophagy in response to chemotherapeutic agents.
Cancer Lett. 344:174–179. 2014. View Article : Google Scholar
|
|
28
|
Pritchard AL and Hayward NK: Molecular
pathways: Mitogen-activated protein kinase pathway mutations and
drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reddy P, Liu L, Ren C, Lindgren P, Boman
K, Shen Y, Lundin E, Ottander U, Rytinki M and Liu K: Formation of
E-cadherin-mediated cell-cell adhesion activates AKT and mitogen
activated protein kinase via phosphatidylinositol 3 kinase and
ligand-independent activation of epidermal growth factor receptor
in ovarian cancer cells. Mol Endocrinol. 19:2564–2578. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsai MS, Weng SH, Chen HJ, Chiu YF, Huang
YC, Tseng SC, Kuo YH and Lin YW: Inhibition of p38 MAPK-dependent
excision repair cross-complementing 1 expression decreases the DNA
repair capacity to sensitize lung cancer cells to etoposide. Mol
Cancer Ther. 11:561–571. 2012. View Article : Google Scholar
|
|
31
|
Csibi A, Fendt SM, Li C, Poulogiannis G,
Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T,
et al: The mTORC1 pathway stimulates glutamine metabolism and cell
proliferation by repressing SIRT4. Cell. 153:840–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Härmä V, Knuuttila M, Virtanen J, Mirtti
T, Kohonen P, Kovanen P, Happonen A, Kaewphan S, Ahonen I,
Kallioniemi O, et al: Lysophosphatidic acid and
sphingosine-1-phosphate promote morphogenesis and block invasion of
prostate cancer cells in three-dimensional organotypic models.
Oncogene. 31:2075–2089. 2012. View Article : Google Scholar :
|
|
35
|
Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi
T and Ogawa O: Activation of caspase-3 in renal cell carcinoma
cells by anthracyclines or 5-fluorouracil. Int J Oncol. 19:19–24.
2001.PubMed/NCBI
|
|
36
|
Samuel T, Fadlalla K, Gales DN, Putcha BD
and Manne U: Variable NF-κB pathway responses in colon cancer cells
treated with chemotherapeutic drugs. BMC Cancer. 14:5992014.
View Article : Google Scholar
|
|
37
|
Shi X, Wu S, Yang Y, Tang L, Wang Y, Dong
J, Lü B, Jiang G and Zhao W: AQP5 silencing suppresses p38 MAPK
signaling and improves drug resistance in colon cancer cells.
Tumour Biol. 35:7035–7045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jeong S, Jing K, Kim N, Shin S, Kim S,
Song KS, Heo JY, Park JH, Seo KS, Han J, et al: Docosahexaenoic
acid-induced apoptosis is mediated by activation of
mitogen-activated protein kinases in human cancer cells. BMC
Cancer. 14:4812014. View Article : Google Scholar : PubMed/NCBI
|
